Mammoth Biosciences, Inc. news

• Agreement strengthens Bayer’s new cell and gene therapy platform further
• Supports Mammoth’s vision of unlocking the full potential of novel CRISPR systems
• Mammoth to receive upfront payment of USD 40 million, and potential future milestone payments of more than one billion USD upon successful achievement

Bayer AG and 

Mammoth Biosciences, a biotech company harnessing next-generation CRISPR technology to detect and cure disease, has been chosen by Endpoints News Editor John Carroll as one of the most promising biotech startups for this year’s Endpoints

• Elaine Sun appointed Chief Operating Officer and Chief Financial Officer
• Ted Tisch appointed Chief Agility Officer
• Adriana Dantas Lemberg joins as Vice President, Product Management, and Dimitrios Zisoulis joins as Vice President, Genome Engineering

Mammoth Biosciences, Inc., today announced that the U.S. Food and Drug Administration (FDA) has granted Emergency Use Authorization (EUA) for its DETECTR BOOST^® SARS-CoV-2 Reagent Kit, a first

Mammoth Biosciences, a biotech company building the next generation of CRISPR products to cure and detect disease, today announced its participation in the upcoming 40th Annual J.P. Morgan Healthcare Conference.

Mammoth’s co-founder and